Abstract
Background
Free light chains (FLC) have been proposed as diagnostic biomarkers in the cerebrospinal fluid (CSF) of patients with inflammatory central nervous system (CNS) diseases. However, which method to use for determining an intrathecal FLC synthesis has not yet been clarified. The objective of this study was to compare the diagnostic performance of CSF FLC concentration, FLC quotient (QFLC), FLC index and FLC intrathecal fraction (FLCIF).
Methods
κ- and λ-FLC were measured by nephelometry under blinded conditions in CSF and serum sample pairs of patients with clinically isolated syndrome (CIS; n = 60), multiple sclerosis (MS; n = 60) and other neurological diseases (n = 60) from four different MS centers. QFLC was calculated as the ratio of CSF/serum FLC concentration, the FLC index as QFLC/albumin quotient and the percentage FLCIF by comparing QFLC to a previously empirically determined, albumin quotient-dependent reference limit.
Results
CSF FLC concentration, QFLC, FLC index and FLCIF of both the κ- and λ-isotype were significantly higher in patients with CIS and MS than in the control group, as well as in oligoclonal bands (OCB) positive than in OCB negative patients. Each parameter was able to identify MS/CIS patients and OCB positivity, however, diagnostic performance determined by receiver operating characteristic (ROC) analyses differed and revealed superiority of FLC index and FLCIF.
Conclusions
These findings support the diagnostic value of FLC measures that correct for serum FLC levels and albumin quotient, i.e. blood-CSF barrier function.
Author contributions: H. Hegen participated in the conception and design of the study, acquisition and statistical analysis of the data, and in drafting the manuscript. J. Walde participated in statistical analysis of the data and in reviewing the manuscript for intellectual content. D. Milosavljevic participated in acquisition of the data and in reviewing the manuscript for intellectual content. F. Aboulenein-Djamshidian participated in acquisition of the data and in reviewing the manuscript for intellectual content. M. Senel participated in acquisition of the data and in reviewing the manuscript for intellectual content. H. Tumani participated in acquisition of the data and in reviewing the manuscript for intellectual content. F. Deisenhammer participated in reviewing the manuscript for intellectual content. S. Presslauer participated in the conception and design of the study, acquisition of the data, and in reviewing the manuscript for intellectual content. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: Multiple Sclerosis Society Vienna. H. Hegen participated in meetings sponsored by, received speaker honoraria or travel funding from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme and Teva, and received honoraria for acting as consultant for Teva. M. Senel received honoraria for speaking and/or travel from Bayer, Biogen, Sanofi Genzyme and TEVA and research funding from the Hertha-Nathorff-Program and University of Ulm, none related to this study. H. Tumani received funding for research projects, lectures and travel from Bayer, Biogen, Genzyme, Fresenius, Merck, Mylan, Novartis, Roche, Siemens Health Diagnostics, Teva, and received research support from Hertie-Stiftung, BMBF, University of Ulm and Landesstiftung BW. F. Deisenhammer participated in meetings sponsored by or received honoraria for acting as an advisor/speaker for Biogen, Celgene, Merck, Novartis, Roche, Sanofi-Genzyme and Teva-Ratiopharm. His institution has received financial support for participation in randomized controlled trials of INFb-1b (Betaferon, Bayer Schering Pharma), INFb-1a (Avonex, Biogen; Rebif, Merck Serono), glatiramer acetate (Copaxone, Teva Pharmaceuticals), Natalizumab (Tysabri, Biogen), in multiple sclerosis. He is section editor of the MSARD journal (Multiple Sclerosis and Related Disorders). S. Presslauer participated in meetings sponsored by Bayer Schering, Biogen Idec, Merck Serono, Novartis and Teva.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F. B cells and multiple sclerosis. Lancet Neurol 2008;7:852–8.10.1016/S1474-4422(08)70192-3Search in Google Scholar PubMed
2. Phares TW, Stohlman SA, Bergmann CC. Intrathecal humoral immunity to encephalitic RNA viruses. Viruses 2013;5:732–52.10.3390/v5020732Search in Google Scholar PubMed PubMed Central
3. Griffin DE. Immune responses to RNA-virus infections of the CNS. Nat Rev Immunol 2003;3:493–502.10.1038/nri1105Search in Google Scholar PubMed PubMed Central
4. Deisenhammer F, Bartos A, Egg R, Gilhus NE, Giovannoni G, Rauer S, et al. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur J Neurol 2006;13:913–22.10.1111/j.1468-1331.2006.01493.xSearch in Google Scholar PubMed
5. Reiber H. Flow rate of cerebrospinal fluid (CSF) – a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci 1994;122:189–203.10.1016/0022-510X(94)90298-4Search in Google Scholar PubMed
6. Souverijn JH, Serrée HM, Peet R, Grenzebach Smit W, Bruyn GW. Intrathecal immunoglobulin synthesis. Comparison of various formulae with the “gold standard” of isoelectric focusing. J Neurol Sci 1991;102:11–6.10.1016/0022-510X(91)90087-NSearch in Google Scholar PubMed
7. Ohman S, Ernerudh J, Forsberg P, Henriksson A, von Schenck H, Vrethem M. Comparison of seven formulae and isoelectrofocusing for determination of intrathecally produced IgG in neurological diseases. Ann Clin Biochem 1992;29 (Pt 4):405–10.10.1177/000456329202900406Search in Google Scholar PubMed
8. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005;62:865–70.10.1001/archneur.62.6.865Search in Google Scholar PubMed
9. Presslauer S, Milosavljevic D, Huebl W, Parigger S, Schneider-Koch G, Bruecke T. Kappa free light chains: diagnostic and prognostic relevance in MS and CIS. PLoS One 2014;9:e89945.10.1371/journal.pone.0089945Search in Google Scholar PubMed PubMed Central
10. Presslauer S, Milosavljevic D, Brücke T, Bayer P, Hübl W. Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J Neurol 2008;255:1508–14.10.1007/s00415-008-0954-zSearch in Google Scholar PubMed
11. Presslauer S, Milosavljevic D, Huebl W, Aboulenein-Djamshidian F, Krugluger W, Deisenhammer F, et al. Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: a multicenter study. Mult Scler 2016;22:502–10.10.1177/1352458515594044Search in Google Scholar PubMed
12. Hegen H, Milosavljevic D, Schnabl C, Manowiecka A, Walde J, Deisenhammer F, et al. Cerebrospinal fluid free light chains as diagnostic biomarker in neuroborreliosis. Clin Chem Lab Med 2018;56:1383–91.10.1515/cclm-2018-0028Search in Google Scholar PubMed
13. Nakano T, Matsui M, Inoue I, Awata T, Katayama S, Murakoshi T. Free immunoglobulin light chain: its biology and implications in diseases. Clin Chim Acta 2011;412:843–9.10.1016/j.cca.2011.03.007Search in Google Scholar PubMed
14. Makshakov G, Nazarov V, Kochetova O, Surkova E, Lapin S, Evdoshenko E. Diagnostic and prognostic value of the cerebrospinal fluid concentration of immunoglobulin free light chains in clinically isolated syndrome with conversion to multiple sclerosis. PLoS One 2015;10:e0143375.10.1371/journal.pone.0143375Search in Google Scholar PubMed PubMed Central
15. Senel M, Tumani H, Lauda F, Presslauer S, Mojib-Yezdani R, Otto M, et al. Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis. PLoS One 2014;9:e88680.10.1371/journal.pone.0088680Search in Google Scholar PubMed PubMed Central
16. Fischer C, Arneth B, Koehler J, Lotz J, Lackner KJ. Kappa free light chains in cerebrospinal fluid as markers of intrathecal immunoglobulin synthesis. Clin Chem 2004;50:1809–13.10.1373/clinchem.2004.033977Search in Google Scholar PubMed
17. Zeman D, Kušnierová P, Bartoš V, Hradílek P, Kurková B, Zapletalová O. Quantitation of free light chains in the cerebrospinal fluid reliably predicts their intrathecal synthesis. Ann Clin Biochem 2016;53(Pt 1):174–6.10.1177/0004563215579110Search in Google Scholar PubMed
18. Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157–74.10.1177/1352458508096878Search in Google Scholar PubMed PubMed Central
19. Polman CH, Reingold SC, Edan G, Filippi M, Hartung H-P, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005;58:840–6.10.1002/ana.20703Search in Google Scholar PubMed
20. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009;73:1914–22.10.1212/WNL.0b013e3181c47cc2Search in Google Scholar PubMed PubMed Central
21. Hoedemakers RM, Pruijt JF, Hol S, Teunissen E, Martens H, Stam P, et al. Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis. Clin Chem Lab Med 2011;50:489–95.10.1515/cclm.2011.793Search in Google Scholar PubMed
22. te Velthuis H, Knop I, Stam P, van den Broek M, Bos HK, Hol S, et al. N Latex FLC – new monoclonal high-performance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med 2011;49:1323–32.10.1515/CCLM.2011.624Search in Google Scholar PubMed
23. Wieand S, Mitchell HG, Barry RJ, Kang LJ. A family of nonparametric statistics for comparing diagnostic markers with paired or unpaired data. Biometrika 1989;76:585–92.10.1093/biomet/76.3.585Search in Google Scholar
24. Duranti F, Pieri M, Centonze D, Buttari F, Bernardini S, Dessi M. Determination of κFLC and κ Index in cerebrospinal fluid: a valid alternative to assess intrathecal immunoglobulin synthesis. J Neuroimmunol 2013;263:116–20.10.1016/j.jneuroim.2013.07.006Search in Google Scholar PubMed
25. Christiansen M, Gjelstrup MC, Stilund M, Christensen T, Petersen T, Jon Møller H. Cerebrospinal fluid free kappa light chains and kappa index perform equal to oligoclonal bands in the diagnosis of multiple sclerosis. Clin Chem Lab Med 2018;57:210–20.10.1515/cclm-2018-0400Search in Google Scholar PubMed
26. Gurtner KM, Shosha E, Bryant SC, Andreguetto BD, Murray DL, Pittock SJ, et al. CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes. Clin Chem Lab Med 2018;56:1071–80.10.1515/cclm-2017-0901Search in Google Scholar PubMed
27. Puthenparampil M, Altinier S, Stropparo E, Zywicki S, Poggiali D, Cazzola C, et al. Intrathecal K free light chain synthesis in multiple sclerosis at clinical onset associates with local IgG production and improves the diagnostic value of cerebrospinal fluid examination. Mult Scler Relat Disord 2018;25:241–5.10.1016/j.msard.2018.08.002Search in Google Scholar PubMed
28. Valencia-Vera E, Martinez-Escribano Garcia-Ripoll A, Enguix A, Abalos-Garcia C, Segovia-Cuevas MJ. Application of κ free light chains in cerebrospinal fluid as a biomarker in multiple sclerosis diagnosis: development of a diagnosis algorithm. Clin Chem Lab Med 2018;56:609–13.10.1515/cclm-2017-0285Search in Google Scholar PubMed
29. Vasilj M, Kes VB, Vrkic N, Vukasovic I. Relevance of KFLC quantification to differentiate clinically isolated syndrome from multiple sclerosis at clinical onset. Clin Neurol Neurosurg 2018;174:220–9.10.1016/j.clineuro.2018.09.031Search in Google Scholar PubMed
30. Emersic A, Anadolli V, Krsnik M, Rot U. Intrathecal immunoglobulin synthesis: The potential value of an adjunct test. Clin Chim Acta 2019;489:109–16.10.1016/j.cca.2018.12.006Search in Google Scholar PubMed
31. Menéndez-Valladares P, García-Sánchez MI, Cuadri Benítez P, Lucas M, Adorna Martínez M, Carranco Galán V, et al. Free kappa light chains in cerebrospinal fluid as a biomarker to assess risk conversion to multiple sclerosis. Mult Scler J Exp Transl Clin 2015;1:2055217315620935.10.1177/2055217315620935Search in Google Scholar PubMed PubMed Central
32. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001;310:173–86.10.1016/S0009-8981(01)00573-3Search in Google Scholar
33. Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci 2001;184:101–22.10.1016/S0022-510X(00)00501-3Search in Google Scholar
34. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215–24.10.1038/leu.2008.307Search in Google Scholar PubMed
©2019 Walter de Gruyter GmbH, Berlin/Boston